Regulatory affairs is the bridge between pharmaceutical companies and government regulatory agencies. It involves all activities related to drugs, including research, clinical trials, manufacturing, registration, distribution, pricing, advertising, and post-marketing surveillance. Regulatory dossiers contain all required technical data and documentation needed to obtain approval to market a drug in a given country or region. Common formats include the Common Technical Document for Europe, US, and other markets and Form 44 for India. Compliance with good practices and local regulations is essential for regulatory approval.
This presentation contains information about dossier preparation and submission as well as about CTD (Common Technical Document) which is an internationally agreed format for the preparation of applications regarding new drugs intended to be submitted to regional regulatory authorities in participating countries.
This presentation contains information about dossier preparation and submission as well as about CTD (Common Technical Document) which is an internationally agreed format for the preparation of applications regarding new drugs intended to be submitted to regional regulatory authorities in participating countries.
Common Technical Document (CTD) serves as a set of specifications for application dossier for the registration of medicines, and designed to be used across Europe, Japan and the United States. The guidelines for CTD are provided by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). TSDP provides clinical medical writing training on preparation of CTD.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
Common Technical Document (CTD) serves as a set of specifications for application dossier for the registration of medicines, and designed to be used across Europe, Japan and the United States. The guidelines for CTD are provided by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). TSDP provides clinical medical writing training on preparation of CTD.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
Registration of Indian Drug Product in Overseas Market.pptxNipun Gupta
This includes the following contents:
1. Introduction
2. Procedure for Export of products
3. Technical Documentations
MFR, BMR, COA, COPP
4. Drug Master File
5. Common Technical Document
6. Electronic Common Technical Documents
7. ASEAN Common Technical Document
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyHitendra Singh
RA is a comparatively new profession which developed from the desire of governments to protect public health by controlling the Quality, safety and efficacy of products in areas including pharmaceuticals, Biotechnology, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines.
Goals of Regulatory Affairs Professionals:-
Protection of human health
Ensuring safety, efficacy and quality of drugs
Ensuring appropriateness and accuracy of product information
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.
For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.
Introduction to Pharma regulatory affairsGIBT India
It constitutes of basic introduction of regulatory affairs in pharmaceuticals, career in pharma regulatory affairs, job opportunities and future aspect. GIBTIndia offers job oriented e- learning courses. Kindly visit us at www.gibtindia.com
Presented at length on 23 April and 21 May 2017 at ICCBS, HEJ and Getz Pharma Auditorium, Karachi in a Discussion Forum of about 800 practicing university qualified professionals of various pharmaceutical manufacturing industries
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
5. 5
• Drug = medicinal product
= pharmaceutical product
6. 6
Drug regulatory affairs
Any activity with drugs
By whom? (the authority)
no (=does not belong to
drug regulatory affairs)
yes
Prior authorisation needed?
Based on which (objective
and subjective) criteria?
Subject to regular control
(quality, inspection)?
By whom? (the authority)
Based on which (objective
and subjective) criteria?
7. 7
Activities with drugs…
• research (chemical, biological)
• clinical trials on human beings
• manufacture
• registration
– evaluation
– authorisation
• (wholesale) distribution
continued
8. 8
Activities with drugs (cont’d)
• pricing
• prescribing
• reimbursement/subsidy
• advertising (if any)
• special control (e.g. narcotics)
• post-marketing surveillance
– national drug quality control lab
– adverse effect reporting system
• (retail) distribution
• etc.
poppy
9. Quality = Quality of Personnel (Qualification, Training…)
+ Quality of Materials (Specifications, Approved Suppliers...)
+ Quality of Means (Qualified equipment's, maintenance…)
+ Quality of Media (GMP premises, Controlled environment…)
+ Quality of Methods (Calibration, Validation…)
Composition of Quality
9
QUALITYQUALITY
Raw Materials
Personnel
Procedures
Validated processes
Equipment
Premises
Environment
Packing Materials
10. Functions of a Quality UnitFunctions of a Quality Unit
10
Quality Control
– Sampling and testing of components Raw materials,
Packing materials, intermediates and finished
products
– Compliance to Good Laboratory Practices (GLPs)
11. Functions of a Quality UnitFunctions of a Quality Unit
11
Quality Assurance
– Designing robust quality systems
– Ensure compliance to relevant
regulatory requirements
– Ensure compliance to
requirements of Good
Manufacturing Practices (GMP)
12. Value addition in QA functionValue addition in QA function
12
Quality Assurance:
– Perform structured self-inspection
audits at regular intervals to prevent
any failure or non-conformance
– Critically analyze the quality non-
conformance issues and suggest
corrective and preventive actions
13. Value addition in QA function
13
Quality Assurance:
– Perform documentation audit to
ensure realistic recording of all the
relevant process parameters
– Review the adequacy of in-process
control checks to prevent any
potential failures
14. Value addition in QA function
14
Quality Assurance:
– Training & Knowledge Management
– Perform literature survey of FDA /
ICH / ISO guidelines, revisions in the
Pharmacopoeial specifications and the
current regulatory requirements and
provide training to the production
personnel.
15. What is Dossier?
15
• Dossier is collection or file of documents that contains all the
technical data of pharmaceutical product to be approved/
registered /marketed in country.
• It is commonly called as registration dossier.
In US : New Drug Application
In EU : Marketing Authorization Application
16. What is DMF?
Drug Master File (DMF)
• US : United State Drug Master File (US-DMF)
• EU : European Drug Master File (EDMF) or
Active Substance Master File (ASMF)
• TYPES OF DMFs
• The types of DMFs are:
• Type I - Manufacturing Site, Facilities, Operating Procedures, and Personnel (no
longer applicable)
• Type II - Drug Substance, Drug Substance Intermediate, and Material Used in
Their Preparation, or Drug Product
• Type III - Packaging Material
• Type IV - Excipient, Colorant, Flavor, Essence, or Material Used in Their
Preparation
• Type V - FDA Accepted Reference Information
16
17. What is CTD/eCTD?
Common Technical Documents (CTD)
• The Common Technical Document (CTD) is a set
of specification for application dossier for the registration
of Medicines and designed to be used across Europe,
United States & ROW.
• Its electronic version called as Electronic Common
Technical Document (eCTD)
17
19. Module 1 Administrative & Prescribing
Information (Region Specific):
Should Contain Documents specific to each region:
19
20. Module 1 Administrative & Prescribing
Information (Region Specific):
(1) SITE MASTER PLAN OF PLANT
(2) COMPANY PROFILE IN SHORT
(3) ATTESTED COPY OF MANUFACTURING LICENCE
(4) ATTESTED COPY OF PRODUCT PERMISSION FROM FDA
(5) ATTESTED COPY OF COPP
(6) ATTESTED COPY OF WHO/GMP CERTIFICATE
(7) COA OF SAMPLE
(8) ATTESTED COPY OF WHOLE SELL LICENCE.
(9) LETTER OF AUTHORISATION
20
22. Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
22
3.1 Table of content (Module 3)3.1 Table of content (Module 3)
3.2 Body of Data3.2 Body of Data
3.2 S Drug Substance3.2 S Drug Substance
3.2 S1 General Information (Name, Mfg.)3.2 S1 General Information (Name, Mfg.)
3.2 S2 Manufacture3.2 S2 Manufacture
3.2 S3 Characterization3.2 S3 Characterization
3.2 S4 Control of Drug Substance
(Specification, Analytical procedures, Validation of
Analytical procedures, etc. )
3.2 S4 Control of Drug Substance
(Specification, Analytical procedures, Validation of
Analytical procedures, etc. )
3.2 S5 Reference Standards3.2 S5 Reference Standards
3.2 S6 Stability3.2 S6 Stability
23. Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
23
3.2 P Drug Product3.2 P Drug Product
3.2 P1 Description and Composition of the Drug Product3.2 P1 Description and Composition of the Drug Product
3.2 P2 Pharmaceutical Development (name, dosage form)3.2 P2 Pharmaceutical Development (name, dosage form)
3.2 P3 Manufacturer3.2 P3 Manufacturer
3.2 P4 Control of Excipients3.2 P4 Control of Excipients
3.2 P5 Control of Drug Product (Specification, Analytical
procedures, Validation of Analytical
procedures, etc. )
3.2 P5 Control of Drug Product (Specification, Analytical
procedures, Validation of Analytical
procedures, etc. )
3.2 P6 Reference Standards3.2 P6 Reference Standards
3.2 P7 Stability3.2 P7 Stability
24. Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
24
3.2 A Appendices3.2 A Appendices
3.2 A1 Facility & Equipment's3.2 A1 Facility & Equipment's
3.2 A2 Advertising agents safety evaluation3.2 A2 Advertising agents safety evaluation
3.2 A3 Excipients3.2 A3 Excipients
3.2 R Regional Information3.2 R Regional Information
3.3 Literature References3.3 Literature References
25. Module 4 Non-Clinical Study Reports:
25
4.1 Table of content (Module 4)4.1 Table of content (Module 4)
4.2 Study Reports4.2 Study Reports
4.2.1 Pharmacology4.2.1 Pharmacology
4.2.1. 1. Pharmacodynamics4.2.1. 1. Pharmacodynamics
4.2.1. 2. Safety Pharmacology4.2.1. 2. Safety Pharmacology
4.2.1. 3. Pharmacodynamics Drug Interaction4.2.1. 3. Pharmacodynamics Drug Interaction
4.2.2 Pharmacokinetics4.2.2 Pharmacokinetics
4.2.2. 1. ADME4.2.2. 1. ADME
4.2.2. 2. Pharmacokinetic Drug Interaction4.2.2. 2. Pharmacokinetic Drug Interaction
4.2.2. 3. Other Pharmacokinetic Study4.2.2. 3. Other Pharmacokinetic Study
26. Module 4 Non-Clinical Study Reports:
26
4.2.3 Toxicology4.2.3 Toxicology
4.2.3. 1. Single/Repeat Dose Toxicity4.2.3. 1. Single/Repeat Dose Toxicity
4.2.3. 2. Genotoxicity4.2.3. 2. Genotoxicity
4.2.3. 3. In-Vivo/Vitro Toxicity4.2.3. 3. In-Vivo/Vitro Toxicity
4.2.3. 4. Carcinogenicity4.2.3. 4. Carcinogenicity
4.2.3. 5. Local Tolerance/Dependence4.2.3. 5. Local Tolerance/Dependence
4.2.3. 6. Other Studies4.2.3. 6. Other Studies
4.3 Literature References4.3 Literature References
27. Module 5 Clinical Study Reports:
27
5.1 Table of content (Module 5)5.1 Table of content (Module 5)
5.2 Tabular listing of Clinical Studies5.2 Tabular listing of Clinical Studies
5.3 Clinical study reports5.3 Clinical study reports
5.3.1 Reports of Biopharmaceutical (BA-BE) Study5.3.1 Reports of Biopharmaceutical (BA-BE) Study
5.3.2 Reports of Pharmacokinetic (biomaterial) study5.3.2 Reports of Pharmacokinetic (biomaterial) study
5.3.3 Reports of Pharmacokinetic (PK) studies5.3.3 Reports of Pharmacokinetic (PK) studies
5.3.4 Reports of Pharmacodynamics (PD) studies5.3.4 Reports of Pharmacodynamics (PD) studies
5.3.4 Reports of Efficacy and Safety studies5.3.4 Reports of Efficacy and Safety studies
5.3.4 Reports of Post-Marketing experience5.3.4 Reports of Post-Marketing experience
5.3.4 Case Report Forms & Individual patient listings5.3.4 Case Report Forms & Individual patient listings
5.4 Literature References5.4 Literature References
30. National (India)
License Application Receipt
Manufacturing license Form No. 24 Form No. 25
Test license Form No. 30 Form No. 29
Import license Form No. 12 Form No.11
30
Compliance to (Drugs & Cosmetics Act 1940 & Rules under)
31. National (India)
Drug Regulatory
approval
Schedule Y Compliance
Form 44
Manufacturing Schedule M Compliance
Documentation Schedule U Compliance
Packaging Schedule P Compliance
API/Excipients/FP/PM IP Inputs if not BP/USP/ or IH
31
32. Regulatory Dossier
Regulatory approach:
Parameters US Europe Other markets India
API USP Ph.Eur. USP / Ph.Eur. IP
USDMF COS (CEP) / EDMF DMF requirement
depends on the
target market
Excipients USP Ph.Eur. USP / Ph.Eur. IP
Reference product US Europe Depends on the
target market
Indian (if not
available, then
US or Europe)
Packaging
materials
Complying to USP Ph.Eur. USP / Ph.Eur. IP
Finished product USP As per Ph.Eur.
General requirement
USP / Ph.Eur. IP
Submission batch 1 2 2 or 3 -
Submission batch
size
100,000 units or
1/10th of commercial
batch
100,000 units or
1/10th of
commercial batch
Depends on the
target market
No such
requirement
32
33. Regulatory Dossier
Regulatory approach:
Parameters US Europe Other markets India
Stability data 1 batch 2 batches 2 or 3 batches 3 batches
Stability condition Zone I & II condition Zone I & II condition Depends on the
target market
Zone IV condition
Comparative
dissolution study
3 media 3 media Depends on the
target market
1 to 3 media
Input materials TSE/BSE, OVI
statements
TSE/BSE Depends on the
target market
No such requirement
Packaging materials Food grade certificate Food grade certificate Depends on the
target market
No such requirement
Method validation data As per ICH ICH ICH No such guideline
Process validation
data
Not required Not required Depends on the
target market
Not required for
submission
Bioequivalence study US reference product
under fast and fed
condition
European reference
product (generally
under fasting condition)
Generally fasting
bio study
Fasting bio study
Bioequivalence study In USFDA approved
CRO anywhere in the
world
MHRA/EU approved
CRO anywhere
Depends on the
target market
Indian study required
33
34. Regulatory Authorities
India: DCGI & State Drug Administration
European Union: MHRA
USA : Food and Drug Administration (FDA)
Australia : Therapeutic Goods Administration
Newzeland : Medsafe
South Africa: Medicines council control
Japan : Ministry of Health & Labour Welfare
Switzerland : Swissmedic
Brazil : ANVISA (The National Health Surveillance Agency)
Mexico: COFEPRIS (The Federal Commission for the Protection against Sanitary Risk)
Chile : ISP - Instituto de Salud Pública de Chile
Columbia: INVIMA – Instituto Nacional de Vigilancia de Medicamentos
Alimentos Carrera 68 D No. 17 - 11 / 21
Argentina: ANMAT - set in 1992 Argentine National Administration of
Drugs, Food & Medical Technology
France: Agence Française de Sécurité Sanitaire des Produits de Santé
Germany: Federal Institute for Drugs and Medical Devices
34